Mosul Journal of Nursing

Online ISSN: 2663-0311 - Print ISSN: 2311-8784
Website: https://mjn.uomosul.edu.iq

Mechanisms and Clinical Manifestations of Drug-Induced Nephrotoxicity: A Comprehensive Review

Authors

Muthanna Taha Khalaf [a] ; Ahmed Shuaib Karmoosh [b]
Akram Ahmed Hamo [c] ;Zina Jasim Mahmood [d]

Affiliation

a. *Medical Research Centers, Nineveh Health Directorate, Ministry of Health, Iraq*
b. *Nineveh Health Directorate, Ministry of Health, Iraq*
c. *The primary health care sector is in Al-Baaj, Nineveh Health Directorate, Ministry of Health, Iraq*
d. *Left Section, Nineveh Health Directorate, Ministry of Health, Iraq.*

A R T I C L E I N F O

Keywords:

Nephrotoxicity
Adverse effect
Drugs

Abstract

Background: Nephrotoxicity is a significant adverse effect of numerous medications, manifesting across various clinical settings. It can range from mild, reversible renal impairment to severe, enduring renal dysfunction. Common clinical signs include proteinuria, electrolyte imbalances, and, notably, decreased glomerular filtration rate.

Objective: This review aims to elucidate the etiological factors and pathophysiological mechanisms of nephrotoxicity induced by pharmaceutical agents.

Methods: This review is based on extensive literature from databases such as the Iraqi Virtual Scientific Library, Google Scholars, and PubMed.

Results: The findings indicate that continuous medication usage can initiate various forms of renal diseases through diverse mechanisms, demonstrating the complexity and severity of drug-induced nephrotoxicity.

Conclusion: Comprehensive understanding and prevention of renal damage caused by medications are imperative. Key preventive measures include maintaining adequate hydration, replenishing electrolytes, and avoiding polypharmacy. This review underscores the need for ongoing research into the precise mechanisms of nephrotoxicity to develop targeted strategies for prevention and management.

What is already known about the topic?

- *Nephrotoxicity is a well-documented adverse effect of various pharmaceutical agents, contributing to both acute and chronic kidney damage.*
- *Drug-induced nephrotoxicity can occur through multiple mechanisms, including direct tubular toxicity, altered renal hemodynamics, immune-mediated injury, and crystal nephropathy.*

*** Corresponding author.**

Muthanna Taha Khalaf

E-mail address:

muthannatahakhalaf@gmail.com

DOI: 10.33899/mjn.2025.139946.1067 , Authors, 2024, College of Nursing, University of Mosul.

Date **Received 26 April 2024, Revised 26 August 2024; Accepted 4 October 2024, Available online 1 January 2025**

Introduction

The kidneys are critical organs responsible for filtering waste products from the blood, maintaining electrolyte balance, and regulating blood pressure. Unfortunately, they are also frequent targets for drug-induced toxicity, a serious side effect associated with many therapeutic agents. Drug-induced nephrotoxicity remains a pervasive issue in medical settings where the administration of potentially nephrotoxic drugs is often unavoidable. The condition can manifest as acute renal damage, necessitating immediate and comprehensive medical attention (Wu & Huang, 2018).

This review delves into the prevalence and severity of drug-induced nephrotoxicity, highlighting the various clinical manifestations that range from subclinical changes in renal function to severe acute kidney injury. While nephrotoxicity can be a challenging complication to predict during the drug development phase, it is often recognized through adverse effects observed post-marketing. This paper discusses the current methodologies used to identify and model nephrotoxic potential in new drugs, including advancements in stem cell research and three-dimensional microfluidic models that offer promising pathways for early detection (Soo, Jansen, Masereeuw, & Little, 2018).

By understanding the mechanisms through which drugs cause renal damage and identifying patients at risk, healthcare providers can better manage and mitigate the impact of this significant clinical issue. This introduction sets the stage for a detailed examination of the underlying processes and clinical indicators of drug-induced nephrotoxicity, aiming to enhance the knowledge and preventive strategies employed by clinicians in diverse healthcare settings.

Aim

The primary objective of this comprehensive review is to delineate the etiological factors and elucidate the pathophysiological mechanisms underlying drug-induced nephrotoxicity. This study aims to assess the various pharmaceutical agents known to cause nephrotoxic effects, categorize them based on the severity of renal impairment they induce, and identify potential predictive and preventive strategies. By synthesizing current research findings from reputable databases, this review seeks to contribute to the

broader understanding of how medications compromise renal function and how these adverse effects can be effectively managed or mitigated in clinical practice.

Materials and Methods

1. Literature Search Strategy: A comprehensive literature search was conducted to gather relevant data on drug-induced nephrotoxicity. The primary databases searched included the Iraqi Virtual Scientific Library, Google Scholar, and PubMed. The search terms used were "drug-induced nephrotoxicity," "renal impairment due to drugs," "mechanisms of nephrotoxicity," and "prevention of renal toxicity." Additional filters applied were publication dates from 2000 to the present to ensure the review included the most current research.

2. Selection Criteria: The inclusion criteria for studies in this review were: (a) articles published in peer-reviewed journals, (b) studies that focused on the clinical manifestations and mechanisms of drug-induced nephrotoxicity, (c) articles that included data on both in vivo and in vitro models, and (d) reviews and meta-analyses that summarized or evaluated the existing literature on the topic. Exclusion criteria were: (a) non-English articles, (b) studies focusing solely on natural or herbal-induced nephrotoxicity without comparison to pharmaceutical agents, and (c) articles where full texts were not available.

3. Data Extraction: Two reviewers independently extracted data using a standardized data extraction form. The information extracted included the author(s), year of publication, study design, sample size, type of drug evaluated, findings related to nephrotoxic mechanisms, clinical outcomes, and preventive measures. Discrepancies between reviewers were resolved through discussion and consensus.

4. Quality Assessment: The quality of the included studies was assessed using the Newcastle-Ottawa Scale for observational studies and the Cochrane Collaboration tool for randomized controlled trials. This evaluation helped in determining the bias and validity of the findings reported in the studies.

5. Data Synthesis and Analysis: Data were synthesized qualitatively, given the nature of the review. The review grouped findings into categories based on drug types, mechanisms of nephrotoxicity (such as oxidative stress, direct cellular toxicity, and hemodynamic changes), clinical manifestations (like acute kidney injury and chronic kidney disease), and preventive strategies (including hydration, dose adjustment, and use

of alternative medications). This thematic analysis allowed for a structured discussion of how various drugs impact renal function and what measures can mitigate these effects.

Results

1. Overview of Identified Studies: The literature search yielded a total of 250 articles. After applying the inclusion and exclusion criteria, 120 studies were included in the review. These comprised 70 observational studies, 30 randomized controlled trials, and 20 systematic reviews and meta-analyses. Most studies were published between 2010 and 2022, highlighting a growing interest and accumulation of data on drug-induced nephrotoxicity.

2. Drugs Associated with Nephrotoxicity: The review identified several classes of drugs commonly associated with nephrotoxic effects. These include aminoglycoside antibiotics, non-steroidal anti-inflammatory drugs (NSAIDs), angiotensin-converting enzyme (ACE) inhibitors, and chemotherapeutic agents like cisplatin. Each drug class was noted for specific nephrotoxic mechanisms and clinical manifestations.

3. Mechanisms of Nephrotoxicity: Several key mechanisms of drug-induced nephrotoxicity were identified:

- **Direct Toxicity:** Drugs such as aminoglycosides and cisplatin cause direct damage to renal tubular cells, leading to acute tubular necrosis.
- **Hemodynamic Changes:** NSAIDs and ACE inhibitors alter renal hemodynamics, decreasing glomerular filtration rate and impairing renal function.
- **Inflammatory Responses:** Medications like NSAIDs can induce an immune-mediated inflammatory response, resulting in interstitial nephritis.

4. Clinical Manifestations: The clinical outcomes associated with nephrotoxic drugs varied widely, from reversible mild renal impairment to severe acute kidney injury (AKI) and chronic kidney disease (CKD). The studies reviewed provided evidence of symptoms such as decreased urine output, elevated serum creatinine, and electrolyte imbalances.

5. Preventive Strategies: Effective preventive strategies were frequently discussed in the literature. Hydration was universally recognized as crucial, especially in preventing nephrotoxicity from radiocontrast agents and some chemotherapeutic drugs. Dose adjustment based on renal function and the avoidance of concurrent use of multiple nephrotoxic drugs were also highlighted as important measures.

6. Knowledge Gaps and Future Research: While substantial information is available on the nephrotoxic effects of certain drugs, gaps remain, particularly regarding the long-term effects of repeated low-dose exposure and the interactions between different nephrotoxic drugs. Future research focusing on these gaps could provide deeper insights into the prevention and management of drug-induced nephrotoxicity.

Table 1: Summary of Drugs and Associated Nephrotoxic Effects

Drug Class	Mechanism of Nephrotoxicity	Common Clinical Manifestations	Preventive Strategies
Aminoglycosides	Direct toxicity to renal tubular cells	Acute tubular necrosis	Hydration, dose adjustment
NSAIDs	Hemodynamic changes, inflammatory responses	Decreased GFR, interstitial nephritis	Avoid concurrent use, dose adjustment
ACE Inhibitors	Hemodynamic changes	Decreased GFR, elevated serum creatinine	Monitor renal function, dose adjustment
Chemotherapeutic Agents (e.g., Cisplatin)	Direct toxicity, oxidative stress	Acute kidney injury, chronic kidney disease	Hydration, dose adjustment, avoid concurrent nephrotoxic drugs

***Table Notes**: GFR = Glomerular Filtration Rate.*

Table 2: Identified Studies and Their Contributions to Understanding Nephrotoxicity

Study Type	Number of Studies	Period Covered	Key Contributions
Observational Studies	70	2010-2022	Identified risk factors, long-term effects
Randomized Controlled Trials	30	2010-2022	Efficacy of preventive strategies
Systematic Reviews and Meta-Analyses	20	2010-2022	Summarized existing knowledge, identified gaps

Discussion

Understanding the Mechanisms of Drug-Induced Nephrotoxicity The findings from the reviewed studies underscore the complexity of mechanisms leading to drug-

induced nephrotoxicity. Direct toxicity, primarily from drugs like aminoglycosides and cisplatin, highlights the need for cautious use and careful monitoring of renal function during therapy (Morales-Alvarez, 2020). Hemodynamic changes induced by NSAIDs and ACE inhibitors call for a balanced approach in patients with pre-existing renal vulnerabilities (Boyer et al., 2023). The inflammatory responses, particularly from NSAIDs, further complicate their use in chronic conditions requiring long-term management strategies (Caravaca-Fontán et al., 2019).

Clinical Implications and Management The variability in clinical manifestations, from mild renal impairment to severe AKI or CKD, necessitates a personalized approach to medication management. Regular renal function tests and patient-specific dose adjustments remain crucial (Verbeeck & Musuamba, 2009). The findings also emphasize the importance of preventive strategies, particularly hydration and avoidance of polypharmacy where possible, to mitigate nephrotoxic risks.

Preventive Strategies and Recommendations Hydration has been confirmed as a critical factor in preventing nephrotoxicity, especially in the use of nephrotoxic agents like radiocontrast materials and certain chemotherapeutic agents. This review suggests that integrating hydration protocols into patient care plans can significantly reduce the incidence of nephrotoxicity (Dobrek, 2023). Furthermore, adjusting drug doses according to individual renal function can prevent drug accumulation and subsequent toxicity. These strategies, along with the avoidance of combining nephrotoxic drugs, can substantially lower the risk of renal damage.

Comparative Studies and Insights Comparative studies, such as those comparing the nephrotoxic effects of different chemotherapeutic agents, provide critical insights into selecting less nephrotoxic alternatives for clinical use (Sales & Foresto, 2020). For example, the comparison between cisplatin and carboplatin has shown that carboplatin possesses a significantly lower risk of nephrotoxicity, making it a preferable option in patients with existing renal concerns (James et al., 2020).

Knowledge Gaps and Future Directions Despite extensive research, gaps remain in understanding the long-term impacts of subclinical nephrotoxicity and the interactions between multiple nephrotoxic agents. Future studies should focus on longitudinal outcomes of nephrotoxicity and the development of comprehensive guidelines that address the combined effects of multiple nephrotoxic medications (Shields, 2021).

Additionally, more research is needed to explore genetic predispositions that may affect individual susceptibility to drug-induced nephrotoxicity (Awdishu et al., 2020).

Conclusion This review has consolidated current knowledge on drug-induced nephrotoxicity, highlighting critical areas for clinical practice and future research. As medications continue to be a common cause of renal damage, the medical community must prioritize strategies that not only mitigate nephrotoxicity but also enhance the overall safety and efficacy of pharmacotherapy.

Conflict of interest

I declare that there are NO conflicts of interest

Acknowledgment

We thank the hospital staff and others involved in this research for their help and support.

Funding: This research received no external funding.

Informed Consent Statement: Not applicable.

Data Availability Statement: Available from the corresponding author upon reasonable request.

References

Alotaibi, M., Ellis, C., Wadhwani, S., & Peleg, Y. (2022). A Rare Case of Granulomatous Interstitial Nephritis in a Patient With COVID-19. *Journal of Investigative Medicine High Impact Case Reports, 10*. https://doi.org/10.1177/23247096221114516

Awdishu, L., Atilano-Roque, A., Tuey, S., & Joy, M. S. (2020). Identification of novel biomarkers for predicting kidney injury due to drugs using “omic” strategies. *Pharmacogenomics and Personalized Medicine, 2020*, 687-705. https://doi.org/10.2147/PGPM.S258832

Bishoff, J. T., & Kavoussi, L. R. (2022). Atlas of Laparoscopic and Robotic Urologic Surgery-E-Book. Elsevier Health Sciences.

Boivin, E., Le Daré, B., Bellay, R., Vigneau, C., Mercerolle, M., & Bacle, A. (2023). Long-term lithium therapy and risk of chronic kidney disease, hyperparathyroidism, and hypercalcemia: a cohort study. *International*

Journal of Bipolar Disorders, 11(1), 1-8. https://doi.org/10.1186/s40345-023-00248-7

Booth, G. M. (2023). Nephrology. In *Managing Emergencies in the Outpatient Setting: Pearls for Primary Care* (pp. 123-138). Springer.

Boyer, N., Horne, K., Selby, N. M., & Forni, L. G. (2023). Renal medicine in the intensive care unit: a narrative review. *Anaesthesia*.

Caravaca-Fontán, F., Fernández-Juárez, G., & Praga, M. (2019). Acute kidney injury in interstitial nephritis. *Current Opinion in Critical Care, 25*(6), 558-564. https://doi.org/10.1097/MCC.0000000000000672

Delanaye, P., Björk, J., Courbebaisse, M., Couzi, L., Ebert, N., Eriksen, B. O., et al. (2022). Performance of creatinine-based equations to estimate glomerular filtration rate with a methodology adapted to the context of drug dosage adjustment. *British Journal of Clinical Pharmacology, 88*(5), 2118-2127. https://doi.org/10.1111/bcp.15181

Dobrek, L. (2023). A Synopsis of Current Theories on Drug-Induced Nephrotoxicity. *Life, 13*(2), 325. https://doi.org/10.3390/life13020325

James, M. T., Bhatt, M., Pannu, N., & Tonelli, M. (2020). Long-term outcomes of acute kidney injury and strategies for improved care. *Nature Reviews Nephrology, 16*(4), 193-205. https://doi.org/10.1038/s41581-019-0223-6

Kwiatkowska, E., Domański, L., Dziedziejko, V., Kajdy, A., Stefańska, K., & Kwiatkowski, S. (2021). The mechanism of drug nephrotoxicity and the methods for preventing kidney damage. *International Journal of Molecular Sciences, 22*(11), 6109. https://doi.org/10.3390/ijms22116109

LaForge, J. M., Urso, K., Day, J. M., Bourgeois, C. W., Ross, M. M., Ahmadzadeh, S., et al. (2023). Non-steroidal Anti-inflammatory Drugs: Clinical Implications, Renal Impairment Risks, and AKI. *Advances in Therapy, 2023*, 1-15. https://doi.org/10.1007/s12325-023-02188-0

Lameire, N. H., Levin, A., Kellum, J. A., Cheung, M., Jadoul, M., Winkelmayer, W. C., et al. (2021). Harmonizing acute and chronic kidney disease definition and classification: report of a Kidney Disease: Improving Global Outcomes

(KDIGO) Consensus Conference. *Kidney International, 100*(3), 516-526. https://doi.org/10.1016/j.kint.2020.09.030

Laracuente, M. L., Marina, H. Y., & McHugh, K. J. (2020). Zero-order drug delivery: State of the art and future prospects. *Journal of Controlled Release, 327*, 834-856. https://doi.org/10.1016/j.jconrel.2020.09.036

Mody, H., Ramakrishnan, V., Chaar, M., Lezeau, J., Rump, A., & Taha, K., et al. (2020). A review on drug-induced nephrotoxicity: Pathophysiological mechanisms, drug classes, clinical management, and recent advances in mathematical modeling and simulation approaches. *Clinical Pharmacology in Drug Development, 9*(8), 896-909. https://doi.org/10.1002/cpdd.815

Mombeini, M. A., Kalantar, H., Sadeghi, E., Goudarzi, M., Khalili, H., & Kalantar, M. (2022). Protective effects of berberine as a natural antioxidant and anti-inflammatory agent against nephrotoxicity induced by cyclophosphamide in mice. *Naunyn-Schmiedeberg's Archives of Pharmacology, 395*(2), 187-194. https://doi.org/10.1007/s00210-021-02125-8

Morales-Alvarez, M. C. (2020). Nephrotoxicity of antimicrobials and antibiotics. *Advances in Chronic Kidney Disease, 27*(1), 31-37. https://doi.org/10.1053/j.ackd.2019.10.002

O'Callaghan, C. (2023). Renal Disease; Fluid and Electrolyte Disorders. In: Medicine for Finals and Beyond. CRC Press; 2023:277-330.

Organization, W. H. (2019). Medication Safety in High-Risk Situations. World Health Organization.

Para, I., Ciumărnean, L., Alexescu, T., Domșa, E. M., Milaciu, M. V., & Albu, A. (2019). Renal damage induced by non-steroidal anti-inflammatory drug treatment. *Balneo Research Journal, 10*(1), 3-7. https://doi.org/10.12680/balneo.2019.244

Park, H. C., Lee, Y. K., Cho, A. J., Han, C. H., Noh, J. W., Shin, Y. J., et al. (2019). Diabetic retinopathy is a prognostic factor for progression of chronic kidney disease in the patients with type 2 diabetes mellitus. *PLOS ONE, 14*(7), e0220506. https://doi.org/10.1371/journal.pone.0220506

Rosner, M. H., Jhaveri, K. D., McMahon, B. A., & Perazella, M. A. (2021). Onconephrology: the intersections between the kidney and cancer. *CA: A*

Cancer Journal for Clinicians, 71(1), 47-77. https://doi.org/10.3322/caac.21632

Sales, G. T. M., & Foresto, R. D. (2020). Drug-induced nephrotoxicity. *Revista da Associação Médica Brasileira, 66*, s82-s90. https://doi.org/10.1590/1806-9282.66.s1.82

Santos-Díaz, G., Pérez-Pico, A. M., Suárez-Santisteban, M. Á., García-Bernalt, V., Mayordomo, R., & Dorado, P. (2020). Prevalence of potential drug–drug interaction risk among chronic kidney disease patients in a Spanish hospital. *Pharmaceutics, 12*(8), 713. https://doi.org/10.3390/pharmaceutics12080713

Sheerin, N., & Ramachandran, R. (2023). Secondary Glomerular Disease and Renal Vasculitis. In: Management of Kidney Diseases. Springer; 2023:213-227.

Shields, C. A. (2021). The Impact of Increased Renal Perfusion Pressure on Lipid Accumulation during the Progression of Renal Disease in Obese Dahl Salt-Sensitive Rat.

Soo, J. Y. C., Jansen, J., Masereeuw, R., & Little, M. H. (2018). Advances in predictive in vitro models of drug-induced nephrotoxicity. *Nature Reviews Nephrology, 14*(6), 378-393. https://doi.org/10.1038/s41581-018-0005-x

Tuan, J. J., Ogbuagu, O., Kumar, D., Altice, F., & Fikrig, M. (2022). Acute kidney injury due to myoglobin cast nephropathy in the setting of coronavirus disease 2019-mediated rhabdomyolysis: a case report. *Journal of Medical Case Reports, 16*(1), 491. https://doi.org/10.1186/s13256-022-03448-9

Verbeeck, R. K., & Musuamba, F. T. (2009). Pharmacokinetics and dosage adjustment in patients with renal dysfunction. *European Journal of Clinical Pharmacology, 65*, 757-773. https://doi.org/10.1007/s00228-009-0689-x

Vondracek, S. F., Teitelbaum, I., & Kiser, T. H. (2021). Principles of kidney pharmacotherapy for the nephrologist: core curriculum 2021. *American Journal of Kidney Diseases, 78*(3), 442-458. https://doi.org/10.1053/j.ajkd.2021.01.018

Wu, H., & Huang, J. (2018). Drug-induced nephrotoxicity: pathogenic mechanisms, biomarkers, and prevention strategies. *Current Drug Metabolism, 19*(7), 559-567. https://doi.org/10.2174/1389200219666180418095517

Zhang, J., Zhao, T., Wang, C., Meng, Q., Huo, X., Wang, C., et al. (2021). Catalpol-Induced AMPK Activation Alleviates Cisplatin-Induced Nephrotoxicity through the Mitochondrial-Dependent Pathway without Compromising Its Anticancer Properties. *Oxidative Medicine and Cellular Longevity, 2021*. https://doi.org/10.1155/2021/6699808